查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2171008

生物標記市場預測：全球市場預測，2026-2032年

Predictive Biomarkers Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，預測性生物標記市場將成長至 827.4 億美元，複合年成長率為 17.61%。

主要市場統計數據
基準年 2025 265.7億美元
預計年份：2026年 308.9億美元
預測年份 2032 827.4億美元
複合年成長率 (%) 17.61%

預測性生物標記：引言及戰略意義

預測性生物標記是可測量的生物學特徵，用於預測患者對特定治療的反應可能性。它們支持治療方案的選擇、臨床試驗參與者的選擇、伴隨診斷的開發，以及在腫瘤學、免疫學、感染疾病和其他治療領域實現更個人化的醫療。其價值取決於分析有效性、臨床有效性、臨床效用、可重複性以及與實際臨床工作流程的整合。

一項將重塑預測性生物標記開發的變革性變化。

該領域正從單一分析檢測轉向結合基因組、轉錄組、蛋白質組、病理和臨床資訊的多模態方法。定序、數位病理、液態生物檢體研究和分散式檢體採集的普及，正在擴大可測量訊號的範圍。同時，監管機構、保險公司、實驗室和醫療服務提供者越來越重視證據品質、檢測標準化、互通性、結果出具時間和公平獲取途徑。

人工智慧如何改變預測性生物標記工作流程

人工智慧正被用於識別候選生物標記、解讀複雜的分子圖譜、分析醫學影像、對臨床試驗參與者進行分層以及輔助預測治療反應。當模型基於具有高度代表性且標註完善的數據進行訓練，並在多個機構和患者群體中檢驗時，其實際應用價值最為顯著。重要的安全措施包括透明的效能報告、偏差評估、人工監督、資料管治、網路安全以及在常規臨床應用前的預期性評估。

區域性預測生物標記生態系洞察

北美受惠於先進的轉化研究、完善的分子檢測基礎設施以及藥物研發與診斷之間的積極合作。歐洲則著重於合作證據產生、資料保護、檢查室品質和跨境監管協調。亞太地區在多個市場展現出強大的研究能力，但檢測可及性、保險報銷和臨床標準化方面存在顯著差異。拉丁美洲正在拓展精準醫療能力，同時持續應對基礎建設、成本效益和人才短缺等挑戰。中東地區加大了對基因組學、專科醫療和國家數據項目的投入，而非洲的需求仍遠未得到滿足，基因組相關計劃正在興起，但檢驗的檢測服務的機會仍然存在差距。

區域洞察：東協、金磚國家、歐盟、七國集團、海灣合作理事會、北約

東協市場在分子檢測領域的成熟度參差不齊，這為制定通用標準、建立區域轉診網路和人力資源開發創造了機會。金磚國家擁有大規模的病患群體和強大的科學研究能力，但在監管體系、資金籌措和醫療服務可近性方面存在差異。歐盟受益於協調一致的科學和監管框架，但其在各成員國之間的執行情況仍不盡相同。七國集團（G7）國家普遍擁有成熟的臨床研究生態系統和完善的檢測基礎設施，但仍面臨成本、互通性和人群代表性的挑戰。海灣合作理事會（GCC）國家正透過集中投資和發展專業化醫療來加強其精準醫療能力。北約成員國的醫療保健體系存在顯著差異，但在建立穩健的生物醫學供應鏈、保障健康數據安全和開展先進的科研合作方面共用共同的願景。

國家概況：市場準備與證據重點

美國和加拿大擁有廣泛的轉化研究和檢測能力，並持續關注醫療報銷、實證標準以及醫療服務取得方面的差異。英國、法國、德國、義大利和西班牙正在結構化的公共衛生體系內推動精準醫療，同時致力於解決轉診途徑和檢查室間合作的差異。中國、日本、韓國、印度和澳洲將先進的研究活動與人口多樣性、監管流程以及都市區醫療服務取得差異等因素結合。巴西、墨西哥和俄羅斯正在醫療融資、基礎設施和專業檢測的可近性方面存在差異，但這些國家仍在發展相關能力。所有國家的優先事項都包括本地化檢驗、標準化分析前程序、臨床醫生教育以及將檢測結果整合到治療方案中。

預測性生物標記領域領導者可採取的行動重點

領導者在選擇技術和終點指標之前，應明確定義生物標記旨在改善的臨床決策。他們還應制定證據檢驗，涵蓋分析有效性、臨床表現、效用、衛生經濟價值和實施後監測。可互通的資料架構、品管的檢查室網路以及臨床醫生、診斷專家、研究人員、監管機構和患者團體之間的夥伴關係，有助於生物標記的實施。此外，各機構還應利用多樣化的資料集，記錄模型的局限性，保護敏感訊息，並制定考慮區域因素、經濟負擔以及醫療系統接收能力的存取策略。

調查方法執行摘要

本概要採用結構化的定性評估方法，對預測性生物標記的開發和應用進行分析，並按技術、臨床工作流程、證據要求、地區和相關人員進行分類。分析基於生物標記檢驗、精準醫療、臨床診斷、人工智慧管治和醫療保健部署等領域的既定原則。區域、群體和國家層級的比較以背景觀察為依據，而非量化排名或市場指標。本概要未使用任何市場估算、預測或公司特定聲明。

結論：建構可靠且無偏的預測性生物標記系統。

當有嚴謹的證據和可靠的實施框架支持時，預測性生物標記可以幫助改善治療方案的選擇，最佳化臨床試驗設計，並促進醫療資源的更有效率利用。在下一階段，可重複性、多模態檢驗、負責任的人工智慧、互通的基礎設施和公平的獲取途徑將比單純的發現更為重要。能夠將科學創新與臨床效用和值得信賴的管治相結合的行業領導者，將更有能力把生物標記的研究成果轉化為對患者有意義的治療結果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物標記市場預測：依生物標記類型分類

  • 基因生物標記
    • DNA突變
    • 拷貝編號變體
    • 基因重排
  • 免疫學生物標記
  • 蛋白質體學生物標記
    • 蛋白質表現
    • 磷酸化蛋白
  • 表觀遺傳生物標記
  • 轉錄組生物標記
    • mRNA表現
    • 微型RNA
  • 代謝體學物標誌物
    • 脂質代謝物
    • 胺基酸代謝物

第8章 預測性生物標記市場：依產品分類

  • 消耗品
    • 檢測試劑盒
    • 檢測套件
    • 試劑
  • 服務
    • 生物標記的發現
    • 生物標記檢驗
    • 臨床生物標記檢測
    • 檢測方法開發
  • 裝置
    • 定序系統
    • PCR系統
    • 質譜系統
    • 免疫檢測裝置
    • 影像系統
    • 流式細胞技術系統
    • 微陣列系統
  • 軟體
    • 生物資訊平台
    • 人工智慧分析

第9章：預測性生物標記市場：依分析技術分類

  • 免疫測量
  • 次世代定序
  • 聚合酵素鏈鎖反應
  • 質譜分析
  • 免疫組織化學
  • 流式細胞技術
  • 微陣列分析
  • 螢光原位雜合反應
  • 基於CRISPR的診斷平台

第10章：預測生物標記市場：依治療領域分類

  • 腫瘤學
    • 肺癌
    • 乳癌
    • 結腸癌
    • 攝護腺癌
    • 淋巴系統惡性腫瘤
    • 髓系惡性腫瘤
    • 黑色素瘤
    • 卵巢癌
    • 胰臟癌
  • 心血管疾病
  • 神經病變
    • 阿茲海默症
    • 帕金森氏症
  • 代謝性疾病
    • 糖尿病
    • 肥胖
  • 自體免疫疾病
  • 感染疾病
    • HIV
    • 肝炎
  • 呼吸系統疾病
  • 腎臟疾病

第11章：生物標記市場預測：依檢測配置分類

  • 多生物標記檢測
  • 單生物標記檢測

第12章 預測性生物標記市場：按應用分類

  • 藥物研發
  • 臨床決策支持
  • 精準醫療
  • 疾病風險預測
  • 藥物基因體學

第13章：預測性生物標記市場：依最終用戶分類

  • 製藥公司
  • 臨床實驗室
  • 生技公司
  • 學術和研究機構
  • 診斷檢查室
  • 醫院
  • 受託研究機構

第14章：預測性生物標記市場：按地區分類

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東
  • 非洲

第15章 預測性生物標記市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第16章 預測性生物標記市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 法國
  • 義大利
  • 加拿大
  • 英國
  • 西班牙
  • 印度
  • 巴西
  • 韓國
  • 澳洲
  • 俄羅斯
  • 墨西哥

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Tempus AI, Inc.
  • Labcorp Holdings Inc.
  • QIAGEN NV
  • Illumina, Inc.
  • Guardant Health, Inc.
  • Revvity, Inc.
  • Myriad Genetics, Inc.
  • Caris Life Sciences, Inc.
  • NeoGenomics, Inc.
  • Quest Diagnostics Incorporated
  • Natera, Inc.
  • Eurofins Scientific SE
  • Agilent Technologies, Inc.
  • IQVIA Holdings Inc.
  • Bio-Rad Laboratories, Inc.
  • Veracyte, Inc.
  • Oxford BioDynamics Plc
  • 10x Genomics, Inc.
  • Abbott Molecular, Inc.
  • Axe Compute Inc.
  • Biodesix, Inc.
  • bioMerieux Inc.
  • BostonGene Corporation
  • Bruker Corporation
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • MDxHealth SA
  • Metabolon, Inc.
  • OncoDNA SA
  • Owkin, Inc.
  • PathAI, Inc.
  • Personalis, Inc.
  • Quanterix Corporation
  • Standard BioTools Inc.
  • Sysmex Corporation

第19章 主要專家

Product Code: MRR-8639DE1748F2

The Predictive Biomarkers Market is projected to grow by USD 82.74 billion at a CAGR of 17.61% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 26.57 billion
Estimated Year [2026] USD 30.89 billion
Forecast Year [2032] USD 82.74 billion
CAGR (%) 17.61%

Predictive Biomarkers: Introduction and Strategic Significance

Predictive biomarkers are measurable biological characteristics used to anticipate how a patient is likely to respond to a specific therapy. They support treatment selection, clinical-trial enrichment, companion-diagnostic development, and more individualized care across oncology, immunology, infectious disease, and other therapeutic areas. Their value depends on analytical validity, clinical validity, clinical utility, reproducibility, and integration into real-world workflows.

Transformative Shifts Reshaping Predictive Biomarker Development

The field is shifting from single-analyte testing toward multimodal approaches that combine genomic, transcriptomic, proteomic, pathological, and clinical information. Broader sequencing access, digital pathology, liquid-biopsy research, and decentralized sample collection are expanding the range of measurable signals. At the same time, regulators, payers, laboratories, and healthcare providers are placing greater emphasis on evidence quality, test standardization, interoperability, turnaround time, and equitable access.

How Artificial Intelligence Is Changing Predictive Biomarker Workflows

Artificial intelligence is being applied to identify candidate biomarkers, interpret complex molecular profiles, analyze medical images, stratify trial participants, and support treatment-response prediction. Its practical contribution is strongest when models are trained on representative, well-annotated data and validated across institutions and patient populations. Key safeguards include transparent performance reporting, bias assessment, human oversight, data governance, cybersecurity, and prospective evaluation before routine clinical use.

Regional Insights Across Predictive Biomarker Ecosystems

North America benefits from advanced translational research, established molecular-testing infrastructure, and active links between drug development and diagnostics. Europe emphasizes coordinated evidence generation, data protection, laboratory quality, and cross-border regulatory alignment. Asia-Pacific combines strong research capacity in several markets with substantial variation in laboratory access, reimbursement, and clinical standardization. Latin America is expanding precision-medicine capabilities while continuing to address infrastructure, affordability, and workforce constraints. The Middle East is investing in genomics, specialized healthcare, and national data programs, whereas Africa presents significant unmet need alongside emerging genomic initiatives and uneven access to validated testing.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets show diverse levels of molecular-testing maturity, creating opportunities for shared standards, regional referral networks, and workforce development. BRICS economies combine major patient populations and research capabilities with differences in regulatory systems, funding, and access. The European Union benefits from coordinated scientific and regulatory frameworks, although implementation remains heterogeneous across member states. G7 countries generally have mature clinical-research ecosystems and stronger laboratory infrastructure, while still confronting cost, interoperability, and population-representation challenges. GCC countries are strengthening precision-health capacity through centralized investment and specialized care. NATO members vary widely in healthcare organization but share interest in resilient biomedical supply chains, secure health data, and advanced research collaboration.

Country Insights: Market Readiness and Evidence Priorities

The United States and Canada have broad translational research and testing capabilities, with continued focus on reimbursement, evidence standards, and access disparities. The United Kingdom, France, Germany, Italy, and Spain are advancing precision medicine within structured public-health systems, while addressing differing adoption pathways and laboratory coordination. China, Japan, South Korea, India, and Australia combine sophisticated research activity with varying population diversity, regulatory processes, and access across urban and rural settings. Brazil, Mexico, and Russia are developing capabilities amid differences in healthcare financing, infrastructure, and availability of specialized testing. Across all countries, priorities include locally representative validation, standardized preanalytics, clinician education, and integration of results into treatment pathways.

Actionable Priorities for Predictive Biomarker Leaders

Leaders should define the clinical decision a biomarker is intended to improve before selecting technologies or endpoints. They should build evidence plans spanning analytical validation, clinical performance, utility, health-economic value, and post-deployment monitoring. Interoperable data architectures, quality-controlled laboratory networks, and partnerships among clinicians, diagnostic specialists, researchers, regulators, and patient groups can improve implementation. Organizations should also use diverse datasets, document model limitations, protect sensitive information, and design access strategies that account for geography, affordability, and health-system capacity.

Research Methodology for the Executive Summary

This summary uses a structured qualitative assessment of predictive-biomarker development and adoption, organized by technology, clinical workflow, evidence requirements, geography, and stakeholder group. Insights are grounded in established principles of biomarker validation, precision medicine, clinical diagnostics, artificial-intelligence governance, and healthcare implementation. Regional, group, and country comparisons are presented as contextual observations rather than quantitative rankings or market measurements. No market estimates, shares, forecasts, or company-specific claims are used.

Conclusion: Building Reliable and Equitable Predictive Biomarker Systems

Predictive biomarkers can make treatment selection more precise, improve trial design, and support more efficient use of healthcare resources when supported by rigorous evidence and dependable implementation. The next phase will depend less on discovery alone and more on reproducibility, multimodal validation, responsible artificial intelligence, interoperable infrastructure, and equitable access. Industry leaders that connect scientific innovation with clinical utility and trustworthy governance will be best positioned to translate biomarker insights into meaningful patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Predictive Biomarkers Market, by Biomarker Type

  • 7.1. Introduction
  • 7.2. Genomic Biomarkers
    • 7.2.1. DNA Mutations
    • 7.2.2. Copy Number Alterations
    • 7.2.3. Gene Rearrangements
  • 7.3. Immunological Biomarkers
  • 7.4. Proteomic Biomarkers
    • 7.4.1. Protein Expression
    • 7.4.2. Phosphoproteins
  • 7.5. Epigenetic Biomarkers
  • 7.6. Transcriptomic Biomarkers
    • 7.6.1. mRNA Expression
    • 7.6.2. microRNA
  • 7.7. Metabolomic Biomarkers
    • 7.7.1. Lipid Metabolites
    • 7.7.2. Amino Acid Metabolites

8. Predictive Biomarkers Market, by Product

  • 8.1. Introduction
  • 8.2. Consumables
    • 8.2.1. Assay Kits
    • 8.2.2. Detection Kits
    • 8.2.3. Reagents
  • 8.3. Services
    • 8.3.1. Biomarker Discovery
    • 8.3.2. Biomarker Validation
    • 8.3.3. Clinical Biomarker Testing
    • 8.3.4. Assay Development
  • 8.4. Instruments
    • 8.4.1. Sequencing Systems
    • 8.4.2. PCR Systems
    • 8.4.3. Mass Spectrometry Systems
    • 8.4.4. Immunoassay Analyzers
    • 8.4.5. Imaging Systems
    • 8.4.6. Flow Cytometry Systems
    • 8.4.7. Microarray Systems
  • 8.5. Software
    • 8.5.1. Bioinformatics Platforms
    • 8.5.2. AI Analytics

9. Predictive Biomarkers Market, by Analytical Technology

  • 9.1. Introduction
  • 9.2. Immunoassays
  • 9.3. Next-Generation Sequencing
  • 9.4. Polymerase Chain Reaction
  • 9.5. Mass Spectrometry
  • 9.6. Immunohistochemistry
  • 9.7. Flow Cytometry
  • 9.8. Microarray Analysis
  • 9.9. Fluorescence In Situ Hybridization
  • 9.10. CRISPR-based Diagnostic Platforms

10. Predictive Biomarkers Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Oncology
    • 10.2.1. Lung Cancer
    • 10.2.2. Breast Cancer
    • 10.2.3. Colorectal Cancer
    • 10.2.4. Prostate Cancer
    • 10.2.5. Lymphoid Malignancies
    • 10.2.6. Myeloid Malignancies
    • 10.2.7. Melanoma
    • 10.2.8. Ovarian Cancer
    • 10.2.9. Pancreatic Cancer
  • 10.3. Cardiovascular Diseases
  • 10.4. Neurological Disorders
    • 10.4.1. Alzheimer's Disease
    • 10.4.2. Parkinson's Disease
  • 10.5. Metabolic Disorders
    • 10.5.1. Diabetes
    • 10.5.2. Obesity
  • 10.6. Autoimmune Diseases
  • 10.7. Infectious Diseases
    • 10.7.1. HIV
    • 10.7.2. Hepatitis
  • 10.8. Respiratory Diseases
  • 10.9. Renal Diseases

11. Predictive Biomarkers Market, by Assay Configuration

  • 11.1. Introduction
  • 11.2. Multi-Biomarker Panels
  • 11.3. Single-Biomarker Assays

12. Predictive Biomarkers Market, by Application

  • 12.1. Introduction
  • 12.2. Drug Development
  • 12.3. Clinical Decision Support
  • 12.4. Precision Medicine
  • 12.5. Disease Risk Prediction
  • 12.6. Pharmacogenomics

13. Predictive Biomarkers Market, by End User

  • 13.1. Introduction
  • 13.2. Pharmaceutical Companies
  • 13.3. Clinical Laboratories
  • 13.4. Biotechnology Companies
  • 13.5. Academic and Research Institutions
  • 13.6. Diagnostic Laboratories
  • 13.7. Hospitals
  • 13.8. Contract Research Organizations

14. Predictive Biomarkers Market, by Region

  • 14.1. Introduction
  • 14.2. North America
  • 14.3. Europe
  • 14.4. Asia-Pacific
  • 14.5. Latin America
  • 14.6. Middle East
  • 14.7. Africa

15. Predictive Biomarkers Market, by Group

  • 15.1. Introduction
  • 15.2. NATO
  • 15.3. G7
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. ASEAN
  • 15.7. GCC

16. Predictive Biomarkers Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. China
  • 16.4. Germany
  • 16.5. Japan
  • 16.6. France
  • 16.7. Italy
  • 16.8. Canada
  • 16.9. United Kingdom
  • 16.10. Spain
  • 16.11. India
  • 16.12. Brazil
  • 16.13. South Korea
  • 16.14. Australia
  • 16.15. Russia
  • 16.16. Mexico

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. F. Hoffmann-La Roche Ltd
  • 18.2. Thermo Fisher Scientific Inc.
  • 18.3. Danaher Corporation
  • 18.4. Tempus AI, Inc.
  • 18.5. Labcorp Holdings Inc.
  • 18.6. QIAGEN N.V.
  • 18.7. Illumina, Inc.
  • 18.8. Guardant Health, Inc.
  • 18.9. Revvity, Inc.
  • 18.10. Myriad Genetics, Inc.
  • 18.11. Caris Life Sciences, Inc.
  • 18.12. NeoGenomics, Inc.
  • 18.13. Quest Diagnostics Incorporated
  • 18.14. Natera, Inc.
  • 18.15. Eurofins Scientific SE
  • 18.16. Agilent Technologies, Inc.
  • 18.17. IQVIA Holdings Inc.
  • 18.18. Bio-Rad Laboratories, Inc.
  • 18.19. Veracyte, Inc.
  • 18.20. Oxford BioDynamics Plc
  • 18.21. 10x Genomics, Inc.
  • 18.22. Abbott Molecular, Inc.
  • 18.23. Axe Compute Inc.
  • 18.24. Biodesix, Inc.
  • 18.25. bioMerieux Inc.
  • 18.26. BostonGene Corporation
  • 18.27. Bruker Corporation
  • 18.28. Charles River Laboratories International, Inc.
  • 18.29. Crown Bioscience, Inc.
  • 18.30. MDxHealth SA
  • 18.31. Metabolon, Inc.
  • 18.32. OncoDNA SA
  • 18.33. Owkin, Inc.
  • 18.34. PathAI, Inc.
  • 18.35. Personalis, Inc.
  • 18.36. Quanterix Corporation
  • 18.37. Standard BioTools Inc.
  • 18.38. Sysmex Corporation

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Predictive Biomarkers Market, Years Considered for the Study
  • FIGURE 2. Global Predictive Biomarkers Market, Research Design
  • FIGURE 3. Global Predictive Biomarkers Market, Research Framework
  • FIGURE 4. Global Predictive Biomarkers Market, Data Triangulation
  • FIGURE 5. Global Predictive Biomarkers Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Predictive Biomarkers Market Size, by Biomarker Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Predictive Biomarkers Market Size, by Biomarker Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Predictive Biomarkers Market Size, by Product, 2025 vs 2032 (%)
  • FIGURE 9. Global Predictive Biomarkers Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Predictive Biomarkers Market Size, by Analytical Technology, 2025 vs 2032 (%)
  • FIGURE 11. Global Predictive Biomarkers Market Size, by Analytical Technology, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Predictive Biomarkers Market Size, by Therapeutic Area, 2025 vs 2032 (%)
  • FIGURE 13. Global Predictive Biomarkers Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Predictive Biomarkers Market Size, by Assay Configuration, 2025 vs 2032 (%)
  • FIGURE 15. Global Predictive Biomarkers Market Size, by Assay Configuration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Predictive Biomarkers Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 17. Global Predictive Biomarkers Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Predictive Biomarkers Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 19. Global Predictive Biomarkers Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Predictive Biomarkers Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global Predictive Biomarkers Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global Predictive Biomarkers Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Predictive Biomarkers Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global Predictive Biomarkers Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global Predictive Biomarkers Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Predictive Biomarkers Market Segmentation & Coverage
  • TABLE 2. Global Predictive Biomarkers Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
  • TABLE 4. Global Genomic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Genomic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Genomic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global DNA Mutations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global DNA Mutations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global DNA Mutations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Copy Number Alterations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Copy Number Alterations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Copy Number Alterations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Gene Rearrangements Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Gene Rearrangements Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Gene Rearrangements Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Immunological Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Immunological Biomarkers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Immunological Biomarkers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Proteomic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Proteomic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Proteomic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Protein Expression Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Protein Expression Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Protein Expression Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Phosphoproteins Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Phosphoproteins Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Phosphoproteins Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Epigenetic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Epigenetic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Epigenetic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Transcriptomic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Transcriptomic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Transcriptomic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global mRNA Expression Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global mRNA Expression Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global mRNA Expression Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global microRNA Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global microRNA Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global microRNA Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Metabolomic Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Metabolomic Biomarkers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Metabolomic Biomarkers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Lipid Metabolites Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Lipid Metabolites Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Lipid Metabolites Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Amino Acid Metabolites Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Amino Acid Metabolites Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Amino Acid Metabolites Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 50. Global Consumables Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Consumables Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Consumables Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Assay Kits Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Assay Kits Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Assay Kits Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Detection Kits Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Detection Kits Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Detection Kits Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Reagents Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Reagents Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Reagents Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Biomarker Discovery Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Biomarker Discovery Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Biomarker Discovery Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Biomarker Validation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Biomarker Validation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Biomarker Validation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Clinical Biomarker Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Clinical Biomarker Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Clinical Biomarker Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Assay Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Global Assay Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 76. Global Assay Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 77. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 78. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 79. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 80. Global Sequencing Systems Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 81. Global Sequencing Systems Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. Global Sequencing Systems Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 83. Global PCR Systems Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 84. Global PCR Systems Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. Global PCR Systems Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 86. Global Mass Spectrometry Systems Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Global Mass Spectrometry Systems Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. Global Mass Spectrometry Systems Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 89. Global Immunoassay Analyzers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 90. Global Immunoassay Analyzers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 91. Global Immunoassay Analyzers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 92. Global Imaging Systems Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Global Imaging Systems Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. Global Imaging Systems Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 95. Global Flow Cytometry Systems Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Global Flow Cytometry Systems Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. Global Flow Cytometry Systems Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 98. Global Microarray Systems Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Global Microarray Systems Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. Global Microarray Systems Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 101. Global Software Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Global Software Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. Global Software Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 104. Global Bioinformatics Platforms Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Global Bioinformatics Platforms Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. Global Bioinformatics Platforms Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 107. Global AI Analytics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Global AI Analytics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. Global AI Analytics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 110. Global Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
  • TABLE 111. Global Immunoassays Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 112. Global Immunoassays Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 113. Global Immunoassays Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 114. Global Next-Generation Sequencing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Global Next-Generation Sequencing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. Global Next-Generation Sequencing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 117. Global Polymerase Chain Reaction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 118. Global Polymerase Chain Reaction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 119. Global Polymerase Chain Reaction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 120. Global Mass Spectrometry Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. Global Mass Spectrometry Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 122. Global Mass Spectrometry Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 123. Global Immunohistochemistry Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 124. Global Immunohistochemistry Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. Global Immunohistochemistry Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 126. Global Flow Cytometry Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 127. Global Flow Cytometry Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 128. Global Flow Cytometry Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 129. Global Microarray Analysis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 130. Global Microarray Analysis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 131. Global Microarray Analysis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 132. Global Fluorescence In Situ Hybridization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 133. Global Fluorescence In Situ Hybridization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 134. Global Fluorescence In Situ Hybridization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 135. Global CRISPR-based Diagnostic Platforms Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 136. Global CRISPR-based Diagnostic Platforms Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. Global CRISPR-based Diagnostic Platforms Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 138. Global Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 139. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 140. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 141. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 142. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 143. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 145. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 146. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 147. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 148. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 149. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 150. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 151. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 152. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 153. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 154. Global Lymphoid Malignancies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 155. Global Lymphoid Malignancies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 156. Global Lymphoid Malignancies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 157. Global Myeloid Malignancies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 158. Global Myeloid Malignancies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 159. Global Myeloid Malignancies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 160. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 161. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 162. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 163. Global Ovarian Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 164. Global Ovarian Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 165. Global Ovarian Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 166. Global Pancreatic Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 167. Global Pancreatic Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 168. Global Pancreatic Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 169. Global Cardiovascular Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 170. Global Cardiovascular Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 171. Global Cardiovascular Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 172. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 173. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 174. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 175. Global Alzheimer's Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 176. Global Alzheimer's Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 177. Global Alzheimer's Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 178. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 179. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 180. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 181. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 182. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 183. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 184. Global Diabetes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 185. Global Diabetes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 186. Global Diabetes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 187. Global Obesity Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 188. Global Obesity Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 189. Global Obesity Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 190. Global Autoimmune Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 191. Global Autoimmune Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 192. Global Autoimmune Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 193. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 194. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 195. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 196. Global HIV Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 197. Global HIV Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 198. Global HIV Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 199. Global Hepatitis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 200. Global Hepatitis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 201. Global Hepatitis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 202. Global Respiratory Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 203. Global Respiratory Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 204. Global Respiratory Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 205. Global Renal Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 206. Global Renal Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 207. Global Renal Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 208. Global Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
  • TABLE 209. Global Multi-Biomarker Panels Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 210. Global Multi-Biomarker Panels Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 211. Global Multi-Biomarker Panels Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 212. Global Single-Biomarker Assays Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 213. Global Single-Biomarker Assays Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 214. Global Single-Biomarker Assays Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 215. Global Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 216. Global Drug Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 217. Global Drug Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 218. Global Drug Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 219. Global Clinical Decision Support Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 220. Global Clinical Decision Support Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 221. Global Clinical Decision Support Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 222. Global Precision Medicine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 223. Global Precision Medicine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 224. Global Precision Medicine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 225. Global Disease Risk Prediction Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 226. Global Disease Risk Prediction Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 227. Global Disease Risk Prediction Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 228. Global Pharmacogenomics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 229. Global Pharmacogenomics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 230. Global Pharmacogenomics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 231. Global Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 232. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 233. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 234. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 235. Global Clinical Laboratories Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 236. Global Clinical Laboratories Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 237. Global Clinical Laboratories Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 238. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 239. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 240. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 241. Global Academic and Research Institutions Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 242. Global Academic and Research Institutions Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 243. Global Academic and Research Institutions Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 244. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 245. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 246. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 247. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 248. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 249. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 250. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 251. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 252. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 253. Global Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 254. North America Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 255. North America Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
  • TABLE 256. North America Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 257. North America Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 258. North America Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 259. North America Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 260. North America Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 261. North America Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 262. North America Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 263. North America Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
  • TABLE 264. North America Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 265. North America Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
  • TABLE 266. North America Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 267. North America Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 268. North America Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 269. North America Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
  • TABLE 270. North America Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 271. North America Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
  • TABLE 272. North America Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 273. North America Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 274. Europe Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 275. Europe Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
  • TABLE 276. Europe Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 277. Europe Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 278. Europe Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 279. Europe Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 280. Europe Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 281. Europe Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 282. Europe Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 283. Europe Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
  • TABLE 284. Europe Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 285. Europe Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
  • TABLE 286. Europe Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 287. Europe Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 288. Europe Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 289. Europe Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
  • TABLE 290. Europe Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 291. Europe Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
  • TABLE 292. Europe Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 293. Europe Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 294. Asia-Pacific Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 295. Asia-Pacific Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
  • TABLE 296. Asia-Pacific Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 297. Asia-Pacific Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 298. Asia-Pacific Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 299. Asia-Pacific Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 300. Asia-Pacific Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 301. Asia-Pacific Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 302. Asia-Pacific Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 303. Asia-Pacific Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
  • TABLE 304. Asia-Pacific Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 305. Asia-Pacific Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
  • TABLE 306. Asia-Pacific Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 307. Asia-Pacific Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 308. Asia-Pacific Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 309. Asia-Pacific Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
  • TABLE 310. Asia-Pacific Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 311. Asia-Pacific Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
  • TABLE 312. Asia-Pacific Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 313. Asia-Pacific Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 314. Latin America Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 315. Latin America Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
  • TABLE 316. Latin America Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 317. Latin America Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 318. Latin America Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 319. Latin America Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 320. Latin America Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 321. Latin America Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 322. Latin America Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 323. Latin America Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
  • TABLE 324. Latin America Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 325. Latin America Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
  • TABLE 326. Latin America Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 327. Latin America Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 328. Latin America Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 329. Latin America Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
  • TABLE 330. Latin America Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 331. Latin America Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
  • TABLE 332. Latin America Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 333. Latin America Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 334. Middle East Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 335. Middle East Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
  • TABLE 336. Middle East Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 337. Middle East Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 338. Middle East Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 339. Middle East Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 340. Middle East Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 341. Middle East Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 342. Middle East Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 343. Middle East Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
  • TABLE 344. Middle East Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 345. Middle East Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
  • TABLE 346. Middle East Predictive Biomarkers Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 347. Middle East Predictive Biomarkers Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 348. Middle East Predictive Biomarkers Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 349. Middle East Predictive Biomarkers Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
  • TABLE 350. Middle East Predictive Biomarkers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 351. Middle East Predictive Biomarkers Market Size, by Assay Configuration, 2017-2032 (USD Million)
  • TABLE 352. Middle East Predictive Biomarkers Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 353. Middle East Predictive Biomarkers Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 354. Africa Predictive Biomarkers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 355. Africa Predictive Biomarkers Market Size, by Biomarker Type, 2017-2032 (USD Million)
  • TABLE 356. Africa Predictive Biomarkers Market Size, by Genomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 357. Africa Predictive Biomarkers Market Size, by Proteomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 358. Africa Predictive Biomarkers Market Size, by Transcriptomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 359. Africa Predictive Biomarkers Market Size, by Metabolomic Biomarkers, 2017-2032 (USD Million)
  • TABLE 360. Africa Predictive Biomarkers Market Size, by Product, 2017-2032 (USD Million)
  • TABLE 361. Africa Predictive Biomarkers Market Size, by Consumables, 2017-2032 (USD Million)
  • TABLE 362. Africa Predictive Biomarkers Market Size, by Services, 2017-2032 (USD Million)
  • TABLE 363. Africa Predictive Biomarkers Market Size, by Instruments, 2017-2032 (USD Million)
  • TABLE 364. Africa Predictive Biomarkers Market Size, by Software, 2017-2032 (USD Million)
  • TABLE 365. Africa Predictive Biomarkers Market Size, by Analytical Technology, 2017-2032 (USD Million)
  • TABLE 366. Af